Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Melanoma 1Leiomyosarcoma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × rubitecan × Clear all
NCT00005873 2013-12-04

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡